PARP-1及其抑制剂在卵巢癌治疗中的研究进展  

Research Progress of PARP-1 and Its Inhibitors in Treatment of Ovarian Cancer

作　　者：杨婧 郑洪 谭娜 YANG Jing;ZHENG Hong;TAN Na(Department of Pathology,Affiliated Hospital of Zunyi Medical University,Zunyi 563000,China)

机构地区：[1]遵义医科大学附属医院病理科

出　　处：《医学综述》2019年第22期4427-4432,共6页Medical Recapitulate

基　　金：贵州省科技合作计划项目(黔科合LH字〔2015〕7455号);遵义市科技计划课题(遵市科合社字〔2018〕85)

摘　　要：卵巢癌早期症状隐匿,临床发现时多属于疾病晚期,其死亡率在妇科恶性肿瘤中最高。聚二磷酸腺苷核糖聚合酶-1(PARP-1)在卵巢癌中高表达,它与卵巢癌的发展、侵袭和预后有密切联系。PARP-1抑制剂可与存在同源重组修复缺陷的肿瘤细胞发生协同致死作用,但不会杀伤正常细胞,若抑制PARP-1介导的单链DNA修复将导致DNA开始半保留复制,随后造成双链DNA损伤,从而导致细胞死亡。因此,PARP-1成为目前卵巢癌靶向治疗的热点。未来,应进一步研究PARP-1及其抑制剂的作用机制和它们的代表药物在卵巢癌中的靶向治疗。Ovarian cancer has concealed early symptoms,and most of the cases are found in late stage,contributing to its highest mortality among gynecologic malignancies.Poly(ADP-ribose)polymerase-1(PARP-1)is highly expressed in ovarian cancer,and it is closely related to the development,invasion and prognosis.PARP-1 inhibitors can be associated with tumor cells with homologous recombination deficiency to generate synergistic lethal effect,but does not kill normal cells.Inhibition of PARP-1 mediated single-stranded DNA repair will lead to DNA semi-reserved replication,which subsequently causes double-stranded DNA damage,leading to cell death.Therefore,PARP-1 has become a hotspot in current ovarian cancer targeted therapy.In the future,the mechanisms of PARP-1 and its inhibitors and the targeted therapy of their representative drugs in ovarian cancer should be further studied.

关 键 词：卵巢癌 聚腺苷酸二磷酸核糖聚合酶-1 聚腺苷酸二磷酸核糖聚合酶抑制剂 

分 类 号：R737.31[医药卫生—肿瘤]